PeptideStack
5.2kquestions
20kanswers
220users

Does nausea at week six of survodutide usually resolve without a dose change?

Asked 11 May 2024Modified 22 months agoViewed 56k times
40

For reference: nausea · six · survodutide.

Everything I have found on this is either a forum aside or a product page, neither of which I trust.

I am comfortable with the arithmetic; what I am missing is the procedural detail around it.

What would you do, and what would you check afterwards?

nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
CL
askedcold_lane10k1611 May 2024
6Which agent and which dose? The rates differ enough to matter. – kwn_analytical 7 months ago
5Voting to keep this open — it is more specific than it first looks. – Dr_Marek_Zielinski 5 months ago
add a comment

5 Answers

Accepted answer first, then by votes
130

Accepted answer

Week 6 is day 42: on a four-week ladder that is week 2 of dose step 2, and — at the seven-day half-life this class runs on — 6 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 42 is 1 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 2 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Nausea in this class tracks the rate of change more than the level: the trial programmes report it clustered in the fortnight after each step and decaying across the weeks that follow, which is why the week number is worth locating on the ladder before anything else. Dose decisions are made under supervision, and nothing here is medical advice.

The honest answer is that it usually settles within one to two weeks at a stable dose, and that the exceptions are the reason to have a clinician.

Tolerance develops through receptor desensitisation over one to two weeks at a stable dose. Escalating before that has happened resets the process, which is the mechanism behind most miserable titrations.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

Alcohol is poorly tolerated in this context for two reasons — delayed emptying alters absorption kinetics, and it irritates a stomach already under strain.

Tachyphylaxis of the gastric-emptying effect with continued exposure is documented for the long-acting agents and is the mechanistic basis for tolerance.

Smaller meals, less fat, stop at first fullness, fluids between meals.

shareimprove this answerflag
EV
answered · acceptedesther_vandeVelde52k274 Aug 2024
Thank you — this is the answer I was looking for. – sian_llewellyn 9 months ago
8I would add a sentence about when to stop managing it and start seeing someone. – m_haraldsen 7 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
40

Persistent vomiting is a different problem from nausea and needs a different response.

Extending the interval before the next escalation is the intervention with the best evidence. Trials titrated at four-week intervals for exactly this reason.

Nausea persisting for more than a few weeks at a stable dose, or accompanied by severe abdominal pain, is outside the ordinary pattern and needs assessment rather than management.

Four-weekly titration intervals in the licensed schedules were chosen to allow tolerance to develop between steps.

Alcohol is a bad idea here for two separate reasons.

edited 19 Sept 2024 by Dr_Nadia_Farsi — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi104k24726 Aug 2024
32

This is the most common adverse effect in the class and the one with the most consistent management advice.

The area postrema lies outside the blood-brain barrier and expresses GLP-1 receptors densely. That is why a large peptide can trigger nausea centrally at all, and why the effect tracks exposure rather than gastric contents.

It helps to be literal here: trial incidence for nausea in this class runs to roughly a quarter to a half of participants depending on agent and dose, concentrated in the escalation phase, with discontinuation for it in low single-figure percentages.

Escalation-related and steady-state nausea are different problems. Establish which you have.

shareimprove this answerflag
TH
answeredtyndall_haze38k387 Sept 2024
29

It helps to be literal here: meal size and composition are the levers that people control and most often ignore.

Practical measures with the most support: smaller meals, stopping at the first sense of fullness, reducing fat and fried foods, avoiding lying flat after eating, and keeping fluid intake up between meals rather than with them.

Area postrema involvement in nausea from GLP-1 receptor agonism is supported by lesion studies in animals and by the anatomy of the circumventricular organs.

Research-use material of unverified content makes any dose-response reasoning unfounded from the start.

Hold the dose rather than escalating. Tolerance needs one to two weeks to develop.

shareimprove this answerflag
TH
answeredthreadlock719k2821 Jun 2024
5Does the tolerance develop at the same rate for the daily agents? – tadhg_o_riordan 7 months ago
6Same experience here, different supplier. – Dr_Wren_Halliday 9 months ago
add a comment
-2

Start with the timing relative to the last dose increase, because escalation-related nausea and steady-state nausea have different explanations and different responses.

Delayed gastric emptying contributes peripherally: a stomach that empties slowly stays full longer, and fullness plus a sensitised trigger zone is the combination that produces the characteristic symptom.

The caveat is that severe or persistent vomiting risks dehydration and electrolyte disturbance, and that is a clinical problem rather than a tolerance question.

Persistent vomiting is a clinical matter, not a tolerance matter.

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi104k24715 Aug 2024
8Any published figure for how long the constipation persists, given it does not attenuate? – Dr_Colm_Fitzhenry 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.